Gastrointestinal Medicines · LP-079
Hyoscine butylbromide Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-079Gastrointestinal Medicines
- Generic identity
- Hyoscine butylbromideTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-079
- Generic identity
- Hyoscine butylbromide
- Presentation
- Tablet
- Catalogue strength
- 10 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Hyoscine butylbromide.
- Dosage form: Tablet.
- Catalogue strength / concentration: 10 mg.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Gastrointestinal Medicines; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Exact salt expression/basis, excipients, coating and tablet alteration instructions.
- Controlled product identity and labelling that prevents salt/product confusion.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 10 mg | Tablet | — | Blister 10 x 10 tablets | Keep hyoscine butylbromide identity explicit; do not transfer evidence from hyoscine/scopolamine hydrobromide products. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Hyoscine butylbromide is an antispasmodic with antimuscarinic effects. It is used in selected conditions involving gastrointestinal or other smooth-muscle spasm. It is distinct from hyoscine hydrobromide, which is used for different purposes and has different effects. This educational profile concerns the butylbromide ingredient and does not establish an approved Luang Pharma indication or identify the cause of abdominal pain. Current national restrictions apply.
Clinical context and therapeutic role
Before selecting an antispasmodic, a professional should assess the pattern of pain and any warning symptoms. Persistent pain, fever, vomiting, blood in the stool or a swollen abdomen may require investigation. Irritable bowel symptoms should not be assumed without an appropriate assessment. The clinician also considers other anticholinergic medicines and conditions affected by reduced smooth-muscle activity. Symptom relief must not delay diagnosis of obstruction, inflammation or another acute abdominal problem.
Selected safety context
Dry mouth, constipation, a faster heartbeat and blurred vision may occur. Narrow-angle glaucoma, urinary retention, myasthenia gravis and suspected bowel obstruction require particular review. Eye pain with visual change needs urgent care. The tablet should not be confused with another hyoscine salt. Severe or persistent abdominal pain, collapse, allergic swelling or breathing difficulty requires assessment. Combining anticholinergic medicines can increase adverse effects and should be discussed with a pharmacist or clinician.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A clinician or pharmacist should assess the cause of symptoms, alarm features and interacting medicines before selecting treatment. Persistent or recurrent symptoms require review. The exact authorized label determines formulation-specific administration and local restrictions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: Hyoscine butylbromide — clinical backgroundArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| NHS: Hyoscine butylbromide — side effectsArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-079.
Professional enquiries
Request product-specific evidence for LP-079.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.